NAD Decline Triggers Lysosomal Failure That Destroys Heart Cell Mitochondria With Age
Scientists map a precise molecular chain linking falling NAD levels to lysosomal dysfunction, cardiolipin loss, and age-related heart failure — and show NAD restoration can reverse it.
Summary
As we age, NAD levels in heart cells fall. This study shows that drop weakens a critical enzyme interaction needed to keep lysosomes acidic. When lysosomes lose their acid environment, a destructive enzyme called cathepsin B leaks into mitochondria and destroys cardiolipin — a lipid essential for mitochondrial energy production. Without cardiolipin, mitochondria become stressed and die, accelerating cardiac dysfunction. The researchers confirmed this chain of events using multiple mouse models and genetic tools. Most importantly, restoring NAD levels rescued lysosomal function, preserved cardiolipin, and protected heart function in both aging rodents and elderly humans. The findings identify v-ATPase and cardiolipin synthesis as promising targets for treating age-related heart failure.
Detailed Summary
Heart failure in older adults is one of the leading causes of death globally, yet the molecular triggers of cardiac aging remain incompletely understood. This study in Circulation identifies a precise mechanistic chain — from declining NAD to lysosomal dysfunction to mitochondrial collapse — that drives age-related cardiomyopathy, and shows it may be reversible.
The central discovery is that falling NAD levels in aging heart cells weaken the interaction between aldolase, a glycolytic enzyme, and v-ATPase, the proton pump that acidifies lysosomes. Without proper acidification, lysosomal membranes become leaky, allowing cathepsin B — a normally contained degradative enzyme — to escape into the mitochondrial compartment.
Once inside mitochondria, cathepsin B disrupts CRLS1, the enzyme responsible for synthesizing and remodeling cardiolipin. Cardiolipin is a unique phospholipid found almost exclusively in mitochondrial inner membranes and is essential for electron transport chain efficiency, membrane integrity, and mitochondrial dynamics. Its depletion triggers oxidative stress and programmed cell death in cardiomyocytes, producing the functional decline characteristic of aging hearts.
The team validated this pathway using RNA sequencing, targeted lipidomics, multiple knockout mouse models, and proximity ligation assays. Crucially, they also tested a nutraceutical intervention to restore NAD levels and found it rescued lysosomal acidification, cardiolipin homeostasis, and cardiac function in both aging mice and elderly human subjects — a rare translational step.
The findings position v-ATPase activity and cardiolipin metabolism as central nodes in cardiac aging and highlight NAD restoration as a tractable therapeutic strategy. Caveats include that the full paper was not available for review, and the human data details — sample size, intervention duration, and endpoints — cannot be evaluated from the abstract alone.
Key Findings
- NAD decline impairs aldolase-v-ATPase interaction, disrupting lysosomal acidification in aging heart cells.
- Lysosomal leakage releases cathepsin B into mitochondria, where it destroys the cardiolipin-synthesizing enzyme CRLS1.
- Cardiolipin deficiency causes mitochondrial oxidative stress and cardiomyocyte death, driving age-related cardiac dysfunction.
- Restoring NAD levels rescued lysosomal function and cardiolipin synthesis in aging rodents and elderly humans.
- Genetic knockout of v-ATPase or CRLS1 in mice reproduces age-related cardiomyopathy, confirming pathway causality.
Methodology
The study combined RNA sequencing, targeted lipidomics, immunofluorescence, co-immunoprecipitation, proximity ligation assays, mitochondrial respiration analysis, and echocardiography. Two v-ATPase knockout mouse models and a CRLS1 knockout model were used to establish causality. A nutraceutical NAD-restoring intervention was tested in aging mouse models and in elderly humans.
Study Limitations
This summary is based on the abstract only, as the full paper was not available; methodology details, sample sizes, and human data quality cannot be fully assessed. The human intervention component lacks described controls, sample size, or statistical detail from the abstract. The nutraceutical used for NAD restoration is not named in the abstract, limiting immediate clinical translation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.